Monday, October 3, 2022

561.316.3330

Biotechnology News Magazine

Akero Therapeutics Reports Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today announced that results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis (NASH) have been published in JHEP Reports. Study results showed that efruxifermin (EFX) was well-tolerated in this cohort of patients with compensated cirrhosis, similar to results observed in the BALANCED main study of patients with pre-cirrhotic NASH.

The paper, available online, provides data on the safety, tolerability, and efficacy of once-weekly subcutaneous injections of 50 mg EFX compared to placebo in Cohort C in adult patients with cirrhotic NASH (compensated stage 4 fibrosis, Child-Pugh Class A), who typically have a worse prognosis and higher mortality than those with an earlier stage of fibrosis. Over 16 weeks of treatment, liver stiffness and serum markers of fibrosis significantly decreased compared to baseline. EFX treatment also improved whole-body metabolism, with significant improvement in lipoprotein profile and decrease in HbA1c.

“These encouraging results reaffirm our confidence in EFX as a potential foundational monotherapy for patients with NASH, including those with advanced-stage fibrosis,” said Kitty Yale, chief development officer of Akero. “We are looking forward to sharing data from our larger Phase 2b HARMONY study in September 2022 and are hopeful they will provide further evidence of EFX’s potential to reverse fibrosis, as well as address the underlying metabolic drivers of the disease. We also look forward to reporting the results of our Phase 2b SYMMETRY study in patients with cirrhotic NASH, which remains on track to be reported in the second half of 2023.”

NASH is a progressive liver disease that can lead to liver cancer, liver failure, and increased risk or cardiac events. There are no approved therapies. EFX is a long-acting FGF21 analog that mimics native FGF21’s biological activities in vitro.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine